DAVID PULLIAM

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 133 - Consolidated Appropriations Act, 2021

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 1425 - Patient Protection and Affordable Care Enhancement Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 133 - Consolidated Appropriations Act, 2021

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 1425 - Patient Protection and Affordable Care Enhancement Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 1865 - Further Consolidated Appropriations Act, 2020

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 133 - Consolidated Appropriations Act, 2021

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 1425 - Patient Protection and Affordable Care Enhancement Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 1425 - Patient Protection and Affordable Care Enhancement Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 133 - Consolidated Appropriations Act, 2021

Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 133 - Consolidated Appropriations Act, 2021

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and value-based purchasing arrangements. H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements. H.R.3 - Lower Drug Costs Now Act H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019 H.R. 7647 - To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products. Medicare Part D reform and benefit redesign. 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and CMS rules related to hospital inpatient payments and value-based purchasing arrangements. S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Advocate on drug pricing proposals, expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act S.3548 - CARES Act H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Issues related to developing new treatment for COVID-19 (2019 Novel Coronavirus). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation of remdesivir. H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.6800 - The Heroes Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. Highlighting Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatment for COVID-19 (2019 Novel Coronavirus), including: clinical trials, expanded access, compassionate use program, emergency use authorization, donation, distribution and allocation, and reimbursement of Veklury (remdesivir). H.R.6201 - Families First Coronavirus Response Act H.R.748 / S.3548 - CARES Act H.R.3 - Lower Drug Costs Now Act of 2019 H.R.6800 - The Heroes Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. S.1416 - Affordable Prescriptions for Patients Act of 2019 S.1895 - Lower Health Care Costs Act H.R.3 - Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act H.R.3 - The Lower Drug Costs Now Act H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R.2740 - HHS Appropriations, 2020 H.R.3164 - FDA Appropriations, 2020 H.R.2839 - Department of State, Foreign Operations, and Related Programs Appropriations Act, 2020 H.R.4378 - Continuing Appropriations Act and Health Extenders Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R.2740 - HHS Appropriations, 2020 H.R.3164 - FDA Appropriations, 2020 H.R.2839 - Department of State, Foreign Operations, and Related Programs Appropriations Act, 2020 H.R.4378 - Continuing Appropriations Act and Health Extenders Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act H.R.3 - The Lower Drug Costs Now Act H.R.259 - Medicaid Extenders Act of 2019

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. S.1416 - Affordable Prescriptions for Patients Act of 2019 S.1895 - Lower Health Care Costs Act H.R.3 - Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R.2740 - HHS Appropriations, 2020 H.R.3164 - FDA Appropriations, 2020 H.R.2839 - Department of State, Foreign Operations, and Related Programs Appropriations Act, 2020 H.R.4378 - Continuing Appropriations Act and Health Extenders Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act

Administration drug pricing proposals. Funding for HCV, HIV and public health activities via appropriations. H.R.2740 - HHS Appropriations, 2020 H.R.3164 - FDA Appropriations, 2020 H.R.2839 - Department of State, Foreign Operations, and Related Programs Appropriations Act, 2020 H.R.4378 - Continuing Appropriations Act and Health Extenders Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. S.1416 - Affordable Prescriptions for Patients Act of 2019 S.1895 - Lower Health Care Costs Act H.R.3 - Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. S.1416 - Affordable Prescriptions for Patients Act of 2019 S.1895 - Lower Health Care Costs Act H.R.3 - Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. S.1416 - Affordable Prescriptions for Patients Act of 2019 S.1895 - Lower Health Care Costs Act H.R.3 - Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act H.R.3 - The Lower Drug Costs Now Act H.R.259 - Medicaid Extenders Act of 2019

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. S.1416 - Affordable Prescriptions for Patients Act of 2019 S.1895 - Lower Health Care Costs Act H.R.3 - Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Expanding access to HIV treatment and prevention therapies including, Administration proposals; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Pharmaceutical policy as it relates to payments under the 340B program. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 S.3013 - Encouraging Innovate Benefit Design to Lower Costs for Seniors Act H.R.1643 - PrEP Assistance Program Act S.1926 - The PrEP Access and Coverage Act

Administration drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including the New Technology Add-On Payment program. Part D benefit redesign. Administration regulations including: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of Pocket Spending"; "Medicare Program; Hospital Inpatient Prospective Payment Systems for Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S.2543 - The Prescription Drug Pricing Reduction Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 H.R.3 - Lower Drug Costs Now Act of 2019 H.R.19 - Lower Costs, More Cures Act of 2019 H.R.259 - Medicaid Extenders Act of 2019

Initiatives relating to the Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act.

Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements.

Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Prison population and hepatitis C. International trade and protection of intellectual property. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements.

Initiatives relating to the Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act.

Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV and HIV portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements.

Initiatives relating to the Administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs"; Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs; coverage and reimbursement policy for HCV, HIV and oncology portfolio. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. Support for H.R. 5353/S.2579 - Eliminating Opioid Related Infectious Diseases Act of 2018. FDA safety requirements. Support for H.R. 6 Sec. 7141 - Support for Patients and Communities Act.